The dose-response relationship observed in trials provides useful clinical guidance
A common pattern is dropping retatrutide from 12 mg to 8 mg/week once cagrilintide is at 1.7-2.4 mg/week
Microbiota-driven changes in deconjugation and downstream transformation can modify the physicochemical properties of bile acids and their reabsorption in the distal ileum, thereby potentially affecting enterohepatic recycling and the relative availability of specific bile acid species within the intestinal lumen (82, 85, 86)
While uncomfortable, these symptoms are typically mild and tend to decrease over time as your system gets used to the medication
Melasma is one of the more commonly treated concerns, and many report improvement but because melasma is hormone- and UV-driven, results are best combined with sun protection and, where relevant, hormonal evaluation